The droplet digital PCR kits, for quality control in cell and gene therapy manufacturing, offer validated workflows for mycoplasma detection, capsid analysis, and residual DNA quantification.
Bio-Rad Laboratories announced the launch of its Vericheck droplet digital PCR (ddPCR) kit portfolio, which is designed for quality control workflows in cell and gene therapy development and other biopharmaceutical applications.
The kits are compatible with the company’s QX700 System. The portfolio includes kits for mycoplasma detection, empty-full capsid, replication-competent lentivirus, and residual DNA quantification for Chinese hamster ovary and E coli.
The QX700 platform enables seven-color multiplexing and has the capacity to process up to 384 reactions in approximately two and a half hours, according to Bio-Rad. The system requires minimal input volume and features continuous loading capability and software for data interpretation. By combining the platform with the Vericheck kits, researchers can generate results for product development, product safety, and quality.
In the development and manufacturing of advanced therapeutics, quality control testing is used to ensure the safety and effectiveness of the product. The new kits provide validated workflows intended to improve confidence in vector characterization and contamination detection, including replication-competent virus testing, and residual host cell DNA quantification.
“The expansion of our range of Vericheck ddPCR Kits offers validated workflows with unmatched precision and sensitivity, combined with the power of the QX700 platform, enabling scalable, streamlined workflows and faster time to actionable results,” says Stephen Kulisch, vice president of marketing of digital biology group at Bio-Rad, in a release.
Bio-Rad states that the expansion of the platform is part of a commitment to support the development of safe and efficient manufacturing for advanced therapeutics.
Photo caption: Vericheck QX700
Photo credit: Bio-Rad Laboratories
